EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial

Markus Ketteler, Andrzej Wiecek, Alexander R Rosenkranz, Claudia Ose, Jan Rekowski, Horst Lorenz, Burkhard Hellmann, Michael Karus, Michaela Ruhmann, Richard Ammer

Nephrology Dialysis Transplantation · 2023

DOI: 10.1093/ndt/gfac206 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nephrology Dialysis Transplantation, 2023. Verfasst von Markus Ketteler und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Internal Medicine and Nephrology, Robert Bosch Hospital, Stuttgart, Germany. Hauptthemen laut MEDLINE: Hyperphosphatemia. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: MEDICE Arzneimittel Pütter GmbH & Co..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We previously reported that modified-release nicotinamide (NAMR) was superior to placebo in reducing serum phosphate concentrations over 12 weeks in a large cohort of haemodialysis patients with hyperphosphataemia. Here we report outcomes after 52 weeks of treatment.

Methods

NOPHOS was a phase 3, international, randomized, controlled, double-blind trial with a parallel group design. NAMR (250–1500 mg/day) was investigated in comparison to placebo as an add-on therapy to an individual therapy with approved phosphate binders.

Results

In the intention-to-treat population (NAMR: n = 539; placebo: n = 183), serum phosphate was significantly lower in the NAMR group compared with the placebo group at week 24 (5.40 ± 1.55 versus 5.79 ± 1.37 mg/dl, P < .001) with a mean difference of −0.39 mg/dl [95% confidence interval (CI) −0.66 to −0.13], but was comparable between the groups at week 52 [mean difference −0.08 (95% CI −0.36–0.20)]. In the completer population (n = 358), statistical significance in favour of NAMR was reached at weeks 24 and 52. The treatment effect was reduced in patients with high baseline serum intact parathyroid hormone (iPTH) compared with patients with low baseline serum iPTH. Compliant patients in the NAMR group had a more pronounced and sustained reduction in serum phosphate than non-compliant patients. NAMR treatment was associated with a significantly increased risk of thrombocytopenia, pruritus, anaemia, and diarrhoea. Herpes zoster occurred exclusively in patients randomized to NAMR.

Conclusions

NAMR combined with phosphate binders significantly reduced serum phosphate over the first 24 weeks of treatment, but the treatment effect was not maintained up to week 52. Non-compliance may have contributed to reduced long-term efficacy. Several newly identified safety signals warrant further evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperphosphatemiaHumansNiacinamideRenal DialysisParathyroid HormonePhosphatesDouble-Blind Method

Stichwörter der Autor:innen

haemodialysishyperphosphataemiamineral and bone diseasenicotinamiderandomized controlled trial

Substanzen

NiacinamideParathyroid HormonePhosphates

Autor:innen und Institutionen

  • Department of General Internal Medicine and Nephrology, Robert Bosch Hospital, Stuttgart, Germany.
  • School of Medicine, University of Split, Split, Croatia.
  • Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland.
  • Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Institute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Center for Clinical Trials, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Förderung

  • MEDICE Arzneimittel Pütter GmbH & Co.

Zitieren

APA

Ketteler, M., Wiecek, A., Rosenkranz, A. R., Ose, C., Rekowski, J., Lorenz, H., Hellmann, B., Karus, M., Ruhmann, M., & Ammer, R. (2023). Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfac206

Vancouver

Ketteler M, Wiecek A, Rosenkranz AR, Ose C, Rekowski J, Lorenz H, et al. Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial. Nephrology Dialysis Transplantation. 2023. doi:10.1093/ndt/gfac206

BibTeX
@article{Ketteler2023,
  author = {Ketteler, Markus and Wiecek, Andrzej and Rosenkranz, Alexander R and Ose, Claudia and Rekowski, Jan and Lorenz, Horst and Hellmann, Burkhard and Karus, Michael and Ruhmann, Michaela and Ammer, Richard},
  title = {Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial},
  journal = {Nephrology Dialysis Transplantation},
  year = {2023},
  doi = {10.1093/ndt/gfac206}
}
Kostenlos starten →